CY1117155T1 - Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl - Google Patents

Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl

Info

Publication number
CY1117155T1
CY1117155T1 CY20161100083T CY161100083T CY1117155T1 CY 1117155 T1 CY1117155 T1 CY 1117155T1 CY 20161100083 T CY20161100083 T CY 20161100083T CY 161100083 T CY161100083 T CY 161100083T CY 1117155 T1 CY1117155 T1 CY 1117155T1
Authority
CY
Cyprus
Prior art keywords
methods
dlbcl
cell
lymphoma
bispecific
Prior art date
Application number
CY20161100083T
Other languages
English (en)
Inventor
Gerhard Zugmaier
Dirk Nagorsen
Juergen Scheele
Original Assignee
Amgen Research (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117155(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh
Publication of CY1117155T1 publication Critical patent/CY1117155T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μέσα και μεθόδους για θεραπευτική αγωγή διάχυτου Β-μεγαλοκυτταρικού λεμφώματος (DLBCL: diffuse large B-cell lymphoma). Συγκεκριμένα, διειδικό αντίσωμα CD19 x CD3 που συμπλέκεται με Τ-λεμφοκύτταρα μέσω του τμήματος του που δεσμεύεται με CD3 και ταυτόχρονα δεσμεύεται με CD19 ειδικότερα στην επιφάνεια κυττάρων λεμφώματος μέσω του τμήματος του που δεσμεύεται με CD19 [δηλαδή, διειδικό Τ-κυτταρο-συμπλεκόμενο μόριο, "BiTE" (bispecific T-cell engager)] χορηγείται για χρήση στην θεραπευτική αγωγή νεοπλασματικής μάζας λεμφοδικτυωτού ιστού και/ή εξιολεμφαδενικού λεμφώματος που προκαλείται από DLBCL σε ασθενή.
CY20161100083T 2010-10-27 2016-01-29 Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl CY1117155T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40710710P 2010-10-27 2010-10-27
EP11787633.4A EP2632954B2 (en) 2010-10-27 2011-10-27 Means and methods for treating dlbcl

Publications (1)

Publication Number Publication Date
CY1117155T1 true CY1117155T1 (el) 2017-04-05

Family

ID=45023802

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161100083T CY1117155T1 (el) 2010-10-27 2016-01-29 Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl
CY20181100508T CY1120227T1 (el) 2010-10-27 2018-05-16 Μεσα και μεθοδοι για την αγωγη dlbcl
CY20201100425T CY1123251T1 (el) 2010-10-27 2020-05-08 Μεθοδοι για την αγωγη dlbcl

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20181100508T CY1120227T1 (el) 2010-10-27 2018-05-16 Μεσα και μεθοδοι για την αγωγη dlbcl
CY20201100425T CY1123251T1 (el) 2010-10-27 2020-05-08 Μεθοδοι για την αγωγη dlbcl

Country Status (31)

Country Link
US (2) US9192665B2 (el)
EP (3) EP3018145B1 (el)
JP (3) JP5997168B2 (el)
KR (1) KR101889995B1 (el)
CN (2) CN105251003B (el)
AU (1) AU2011322581B2 (el)
CA (1) CA2815119C (el)
CL (1) CL2013001138A1 (el)
CR (1) CR20130245A (el)
CY (3) CY1117155T1 (el)
DK (3) DK3412687T3 (el)
EA (1) EA032139B1 (el)
ES (3) ES2675299T3 (el)
HK (1) HK1188229A1 (el)
HR (2) HRP20151444T4 (el)
HU (3) HUE027678T2 (el)
IL (3) IL225924A (el)
LT (2) LT3018145T (el)
MA (1) MA34619B1 (el)
ME (1) ME02311B (el)
MY (1) MY163057A (el)
NZ (2) NZ701715A (el)
PL (3) PL3412687T3 (el)
PT (3) PT2632954E (el)
RS (3) RS60094B1 (el)
SG (1) SG189869A1 (el)
SI (3) SI2632954T2 (el)
SM (1) SMT201600050B (el)
TR (1) TR201808019T4 (el)
UA (1) UA111175C2 (el)
WO (1) WO2012055961A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5129122B2 (ja) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
SG189869A1 (en) * 2010-10-27 2013-06-28 Amgen Res Munich Gmbh Means and methods for treating dlbcl
CA2816668C (en) 2010-11-10 2021-03-23 Amgen Research (Munich) Gmbh Prevention of adverse effects caused by cd3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2019532017A (ja) 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
PT3445787T (pt) 2016-10-07 2021-03-15 Tcr2 Therapeutics Inc Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão
KR20230172612A (ko) 2016-10-19 2023-12-22 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
US20220023430A1 (en) * 2018-11-13 2022-01-27 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
TW202108150A (zh) * 2019-05-03 2021-03-01 美商凱特製藥公司 投與嵌合抗原受體免疫療法之方法
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022117799A2 (en) * 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US10000574B2 (en) 2003-11-28 2018-06-19 Amgen Research (Munich) Gmbh Compositions comprising polypeptides
CA2597924C (en) 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
JP5129122B2 (ja) * 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
CA2633594C (en) * 2005-12-16 2021-10-26 Micromet Ag Means and methods for the treatment of tumorous diseases
ATE551071T1 (de) 2006-09-08 2012-04-15 Medimmune Llc Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
LT2982696T (lt) * 2008-11-07 2019-06-10 Amgen Research (Munich) Gmbh Ūmios limfoblastinės leukemijos gydymas
ME02947B (me) 2009-10-27 2018-04-20 Amgen Res Munich Gmbh Režim doziranja kod primjene dvojno specifičnog protutijela cd19xcd3
SG189869A1 (en) * 2010-10-27 2013-06-28 Amgen Res Munich Gmbh Means and methods for treating dlbcl

Also Published As

Publication number Publication date
IL260774B (en) 2019-02-28
IL225924A (en) 2017-12-31
HRP20180882T1 (hr) 2018-07-27
HUE037786T2 (hu) 2018-09-28
CY1123251T1 (el) 2021-10-29
JP2016164192A (ja) 2016-09-08
LT3412687T (lt) 2020-07-27
JP5997168B2 (ja) 2016-09-28
HUE027678T2 (en) 2016-11-28
ES2675299T3 (es) 2018-07-10
EP2632954B2 (en) 2021-07-07
CR20130245A (es) 2013-09-20
ES2563439T5 (es) 2022-02-04
IL225924A0 (en) 2013-06-27
HRP20151444T1 (hr) 2016-01-29
CY1120227T1 (el) 2018-12-12
KR101889995B1 (ko) 2018-08-20
PL3018145T3 (pl) 2018-09-28
UA111175C2 (uk) 2016-04-11
KR20140019298A (ko) 2014-02-14
JP2013540799A (ja) 2013-11-07
EP2632954B1 (en) 2015-11-25
SI2632954T2 (sl) 2021-11-30
PL2632954T5 (pl) 2021-11-02
LT3018145T (lt) 2018-05-10
JP6522722B2 (ja) 2019-05-29
US20130287778A1 (en) 2013-10-31
CN105251003B (zh) 2019-08-02
RS60094B1 (sr) 2020-05-29
RS54525B2 (sr) 2021-08-31
CA2815119A1 (en) 2012-05-03
EA201390387A1 (ru) 2013-10-30
PL3412687T3 (pl) 2020-07-27
IL256110B (en) 2018-08-30
AU2011322581A1 (en) 2013-05-09
US20160208001A1 (en) 2016-07-21
US9192665B2 (en) 2015-11-24
WO2012055961A1 (en) 2012-05-03
NZ701715A (en) 2016-05-27
ES2563439T3 (es) 2016-03-15
AU2011322581B2 (en) 2015-04-23
ME02311B (me) 2016-06-20
CA2815119C (en) 2023-01-10
JP2018039838A (ja) 2018-03-15
SG189869A1 (en) 2013-06-28
DK2632954T3 (en) 2016-02-01
PL2632954T3 (pl) 2016-05-31
PT3018145T (pt) 2018-05-17
EP2632954A1 (en) 2013-09-04
MA34619B1 (fr) 2013-10-02
CN103459425A (zh) 2013-12-18
CN103459425B (zh) 2015-11-25
PT3412687T (pt) 2020-04-03
DK2632954T4 (da) 2021-08-09
SI3412687T1 (sl) 2020-07-31
HK1188229A1 (en) 2014-04-25
TR201808019T4 (tr) 2018-06-21
DK3412687T3 (da) 2020-05-11
SI3018145T1 (en) 2018-08-31
RS57260B1 (sr) 2018-08-31
EA032139B1 (ru) 2019-04-30
IL256110A (en) 2018-02-28
EP3018145B1 (en) 2018-04-04
EP3412687A1 (en) 2018-12-12
EP3018145A1 (en) 2016-05-11
EP3412687B1 (en) 2020-03-18
SMT201600050B (it) 2016-04-29
NZ719768A (en) 2021-07-30
PT2632954E (pt) 2016-02-03
RS54525B1 (en) 2016-06-30
CL2013001138A1 (es) 2014-11-14
ES2787044T3 (es) 2020-10-14
NZ609201A (en) 2015-01-30
MY163057A (en) 2017-08-15
SI2632954T1 (sl) 2016-02-29
CN105251003A (zh) 2016-01-20
HUE048639T2 (hu) 2020-08-28
DK3018145T3 (en) 2018-05-28
US10696744B2 (en) 2020-06-30
HRP20151444T4 (hr) 2021-08-20
JP6254220B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
CY1117155T1 (el) Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl
CY1121331T1 (el) Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
CY1113984T1 (el) Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων
PH12017501368A1 (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
CY1117992T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε huluc63 μαζι με bortezomib
NZ626610A (en) Antibodies that bind csf1r
CY1124281T1 (el) Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες
NZ631405A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
EA201691858A1 (ru) Композиции антител для лечения опухолей
CY1116488T1 (el) Αντισωματα anti-προπερδινης
PH12015500125A1 (en) Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
CY1115932T1 (el) Σκευασμα αντισωματος
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
MX2021006395A (es) Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso.
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
NZ624059A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
CY1123398T1 (el) Συνθεση συνδυασμου
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
TR201904882T4 (tr) Tıbbi kullanım için bispesifik antikorlar.